References
[1] Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl S29):1-464.
[2] Bleier BS. Topical glucocorticoid treatment for chronic rhinosinusitis in the biologic era. Int Forum Allergy Rhinol. 2020;10(8):933-935.
[3] Simmonds JC, Paz-Lansberg M, Scangas G, Metson R. Endoscopic sinus surgery for chronic rhinosinusitis: 22-item Sino-Nasal Outcome Test 5-year results. Int Forum Allergy Rhinol. 2022;12(3):257-265.
[4] Miglani A, Divekar RD, Azar A, Rank MA, Lal D. Revision endoscopic sinus surgery rates by chronic rhinosinusitis subtype. Int Forum Allergy Rhinol. 2018;8(9):1047-1051.
[5] Dietz de Loos DA, Hopkins C, Fokkens WJ. Symptoms in chronic rhinosinusitis with and without nasal polyps. Laryngoscope. 2013;123(1):57-63.
[6] Akmal M, Hasnain N, Rehan A, et al. Glioblastome Multiforme: A Bibliometric Analysis. World Neurosurg. 2020;136:270-282.
[7] Devos P, Menard J. Bibliometric analysis of research relating to hypertension reported over the period 1997-2016. J Hypertens. 2019;37(11):2116-2122.
[8] Gienapp AJ, Pippenger W, McGregor AL, Fulton SP. Publications in Pediatric Epilepsy: Using Bibliometrics to Determine Readings in the Field. J Child Neurol. 2022;37(8-9):717-726.
[9] Ahmad P, Slots J. A bibliometric analysis of periodontology. Periodontol 2000. 2021;85(1):237-240.
[10] Wilson M, Sampson M, Barrowman N, Doja A. Bibliometric Analysis of Neurology Articles Published in General Medicine Journals. JAMA Netw Open. 2021;4(4):e215840.
[11] Luo X, Zhong R, Wang X, et al. Twenty-year span of global acute pancreatitis trends: A bibliometric analysis. Pancreatology. 2022;22(3):356-366.
[12] van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523-538.
[13] Pan X, Yan E, Cui M, Hua W. Examining the Usage, Citation, and Diffusion Patterns of Bibliometric Mapping Software: A Comparative Study of Three Tools. J Informetrics (2018) 12(2):481–93.
[14] Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724-728.
[15] Wu F, Gao J, Kang J, et al. Knowledge Mapping of Exosomes in Autoimmune Diseases: A Bibliometric Analysis (2002-2021). Front Immunol. 2022;13:939433.
[16] Sun HL, Bai W, Li XH, et al. Schizophrenia and Inflammation Research: A Bibliometric Analysis. Front Immunol. 2022;13:907851.
[17] Ma D, Yang B, Guan B, et al. A Bibliometric Analysis of Pyroptosis From 2001 to 2021. Front Immunol. 2021;12:731933.
[18] Venable GT, Shepherd BA, Loftis CM, et al. Bradford’s law: identification of the core journals for neurosurgery and its subspecialties. J Neurosurg. 2016;124(2):569-579.
[19] Brookes BC. Bradford’s law and the bibliography of science. Nature. 1969;224(5223):953-956.
[20] Fokkens WJ, Lund VJ, Mullol J, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012;23:3-298.
[21] Lund VJ, Mackay IS. Staging in rhinosinusitus. Rhinology. 1993 Dec;31(4):183-4.
[22] Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280-1289.
[23] Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol. 2016;137(5):1449-1456.e4.
[24] Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5):1023-1042.
[25] Seegräber M, Srour J, Walter A, Knop M, Wollenberg A. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018 May;11(5):467-474.
[26] Siddiqui S, Bachert C, Chaker AM, et al. AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps. ERJ Open Res. 2022;8(4):00085-2022.
[27] Bachert C, Khan AH, Hopkins C, et al. Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP. J Asthma Allergy. 2022;15:557-563.
[28] Migueres N, Poirot A, Zhang N, Bachert C, de Blay F. Omalizumab effectiveness is independent of Staphylococcal Enterotoxin sensitization [published online ahead of print, 2022 Dec 13]. Respir Med Res. 2022;83:100986.
[29] Bachert C, Sousa AR, Han JK, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. J Allergy Clin Immunol. 2022;149(5):1711-1721.e6.
[30] Wang Z, Wang Q, Duan S, et al. A diagnostic model for predicting type 2 nasal polyps using biomarkers in nasal secretion. Front Immunol. 2022;13:1054201.
[31] Förster-Ruhrmann U, Szczepek AJ, Pierchalla G, et al. Chemokine Expression-Based Endotype Clustering of Chronic Rhinosinusitis. J Pers Med. 2022;12(4):646.
[32] Plath M, Derycke L, Sand M, et al. Can patient-reported outcomes and inflammatory markers define endotype 2 in chronic rhinosinusitis without nasal polyps? [published online ahead of print, 2022 Nov 25]. Ann Allergy Asthma Immunol. 2022;S1081-1206(22)01961-5.
[33] Wang X, Sima Y, Zhao Y, et al. Endotypes of chronic rhinosinusitis based on inflammatory and remodeling factors [published online ahead of print, 2022 Oct 19]. J Allergy Clin Immunol. 2022;S0091-6749(22)01377-X.
[34] Shen Y, Zhang N, Yang Y, Hong S, Bachert C. Local Immunoglobulin E in nasal polyps: Role and modulation. Front Immunol. 2022;13:961503.
[35] Gomes SC, Cavaliere C, Masieri S, et al. Reboot surgery for chronic rhinosinusitis with nasal polyposis: recurrence and smell kinetics. Eur Arch Otorhinolaryngol. 2022;279(12):5691-5699.
[36] Sakashita M, Takabayashi T, Imoto Y, et al. Retinoic acid promotes fibrinolysis and may regulate polyp formation. J Allergy Clin Immunol. 2022;150(5):1114-1124.e3.
[37] Chen CL, Zhao JF, Guo CL, et al. Nasal secretion tissue plasminogen activator: A novel effective predictor of nasal polyp recurrence. J Allergy Clin Immunol Pract. 2022;10(8):2191-2194.e3.
[38] Price CPE, Guo A, Stevens WW, et al. Efficacy of an oral CRTH2 antagonist (AZD1981) in the treatment of chronic rhinosinusitis with nasal polyps in adults: A randomized controlled clinical trial. Clin Exp Allergy. 2022;52(7):859-867.
[39] Mattos JL, Hasan S, Schlosser RJ, Payne SC, Soler ZM. The association of gustatory dysfunction, olfactory dysfunction, and cognition in older adults [published online ahead of print, 2022 Dec 23]. Int Forum Allergy Rhinol. 2022;10.1002/alr.23126.
[40] Schlosser RJ, Dubno JR, Eckert MA, et al. Unsupervised Clustering of Olfactory Phenotypes. Am J Rhinol Allergy. 2022;36(6):796-803.
[41] Pandrangi VC, Mace JC, Kim JH, et al. Work productivity and activity impairment in patients with chronic rhinosinusitis undergoing endoscopic sinus surgery-A prospective, multi-institutional study [published online ahead of print, 2022 Aug 8]. Int Forum Allergy Rhinol. 2022;10.1002/alr.23070.
[42] Fokkens W, Trigg A, Lee SE, et al. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study. J Patient Rep Outcomes. 2023;7(1):4.
[43] Gevaert P, Lee SE, Settipane RA, et al. Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps. Clin Transl Immunology. 2023;12(1):e1433.
[44] Cao PP, Li HB, Wang BF, et al. Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol. 2009;124(3):478-484.e4842.
[45] Zhang N, Van Zele T, Perez-Novo C, et al. Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease. J Allergy Clin Immunol. 2008;122(5):961-968.
[46] Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol. 2001;107(4):607-614.
[47] Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34(5):447-454.
[48] Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-6.e1.
[49] Hastan D, Fokkens WJ, Bachert C, et al. Chronic rhinosinusitis in Europe–an underestimated disease. A GA²LEN study. Allergy. 2011;66(9):1216-1223.